22nd Century Group Reports Third Quarter 2025 Financial Results
Alvotech (NASDAQ: ALVO) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York from September 8–10, 2025. The company will meet investors on September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will take part in a fireside chat on September 10, 2025 at 10:45 am EDT (14:45 GMT / 16:45 CET). A live webcast of the fireside chat will be publicly available at the company investor events page.
A recording of the session will be available for replay for 90 days after the event.
Alvotech (NASDAQ: ALVO) parteciperà alla Morgan Stanley 23rd Annual Global Healthcare Conference a New York dal 8 al 10 settembre 2025. L'azienda incontrerà gli investitori il 9 settembre 2025, e il dottor Balaji Prasad, Chief Strategy Officer, parteciperà a una chiacchierata informale il 10 settembre 2025 alle ore 10:45 EDT (14:45 GMT / 16:45 CET). Una trasmissione in diretta della chiacchierata sarà pubblicamente disponibile sulla pagina degli eventi per investitori dell'azienda.
Una registrazione della sessione sarà disponibile in replay per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO) participará en la Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York del 8 al 10 de septiembre de 2025. La empresa se reunirá con inversores el 9 de septiembre de 2025, y el Dr. Balaji Prasad, Director de Estrategia, formará parte de una charla junto a la chimenea el 10 de septiembre de 2025 a las 10:45 a. m. EDT (14:45 GMT / 16:45 CET). Una transmisión en vivo de la charla estará disponible públicamente en la página de eventos para inversores de la empresa.
Una grabación de la sesión estará disponible para su reproducción durante 90 días después del evento.
Alvotech (NASDAQ: ALVO)는 뉴욕에서 열리는 Morgan Stanley 23rd Annual Global Healthcare Conference에 참석할 예정이며, 2025년 9월 8–10일에 개최됩니다. 회사는 2025년 9월 9일에 투자자들을 만날 것이고, Balaji Prasad 박사, 최고 전략 책임자,는 2025년 9월 10일 10:45am EDT (14:45 GMT / 16:45 CET)에 화롯대 대화에 참가합니다. 화롯대 대화의 생중계는 회사의 투자자 이벤트 페이지에서 공개적으로 이용 가능할 것입니다.
세션의 녹화는 이벤트 후 90일 동안 재생을 위해 이용 가능합니다.
Alvotech (NASDAQ: ALVO) participera à la Morgan Stanley 23rd Annual Global Healthcare Conference à New York du 8 au 10 septembre 2025. L'entreprise rencontrera les investisseurs le 9 septembre 2025, et le Dr Balaji Prasad, Directeur de la Stratégie, participera à une discussion informelle le 10 septembre 2025 à 10h45 EDT (14h45 GMT / 16h45 CET). Une diffusion en direct de la discussion sera publiquement disponible sur la page des événements pour investisseurs de l'entreprise.
Un enregistrement de la session sera disponible en replay pour 90 jours après l'événement.
Alvotech (NASDAQ: ALVO) nimmt an der Morgan Stanley 23rd Annual Global Healthcare Conference in New York vom 8. bis 10. September 2025 teil. Das Unternehmen wird sich am 9. September 2025 mit Investoren treffen, und Dr. Balaji Prasad, Chief Strategy Officer, wird an einem Fireside Chat am 10. September 2025 um 10:45 Uhr EDT (14:45 GMT / 16:45 CET) teilnehmen. Eine Live-Übertragung des Fireside Chats wird öffentlich auf der Seite der Unternehmensinvestorenevents verfügbar sein.
Eine Aufnahme der Sitzung wird für die Wiedergabe für 90 Tage nach der Veranstaltung verfügbar sein.
Alvotech (NASDAQ: ALVO) ستشارك في Morgan Stanley 23rd Annual Global Healthcare Conference في نيويورك من 8 إلى 10 سبتمبر 2025. ستلتقي الشركة بالمستثمرين في 9 سبتمبر 2025، وسيشارك الدكتور بالاجي برساد، كبير مسؤولي الإستراتيجية، في جلسة حديثة حول المدفأة 10 سبتمبر 2025 في الساعة 10:45 صباحاً بتوقيت شرق الولايات المتحدة (14:45 GMT / 16:45 CET). ستتوفر بث حي للجلسة على صفحة فعاليات المستثمرين الخاصة بالشركة علناً.
سيكون تسجيل الجلسة متاحاً للمشاهدة مرة أخرى لمدة 90 يوماً بعد الحدث.
- None.
 
- None.
 
REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET).
A live webcast of the fireside chat will be available to the general public and can be accessed at https://investors.alvotech.com/events/event-details/morgan-stanley-23rd-annual-global-healthcare-conference-new-york. After the event, a recording will be available for replay for 90 days.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com.
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS 
Benedikt Stefansson, VP
alvotech.ir@alvotech.com